Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology


  1. Published

    Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

    Bastholt, L., Schmidt, H., Bjerregaard, J. K., Herrstedt, Jørn & Svane, Inge Marie, Sep 2019, In: European journal of cancer (Oxford, England : 1990). 119, p. 122-131 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Martinenaite, E., Ahmad, S. M., Bendtsen, S. K., Jørgensen, M. A., Weis-Banke, S. E., Svane, Inge Marie & Andersen, Mads Hald, 2019, In: Cancer Immunology, Immunotherapy. 68, 11, p. 1901-1907 7 p.

    Research output: Contribution to journalReviewResearchpeer-review

  3. Published

    Assessment of extracellular matrix and tissue derived metabolites in a liquid biopsy for identifying endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment.

    Willumsen, N., Bager, C. L., Jensen, C., Karsdal, M. A., Madsen, Daniel Hargbøl, Hansen, M., Schmidt, H. & Svane, Inge Marie, 2019, In: Journal of Clinical Oncology. 37, 15_suppl, e14050.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Published

    B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-α2, or combination treatment

    Sørensen, A. L., Bjørn, M. E., Riley, C. H., Holmstrøm, M., Andersen, Mads Hald, Svane, Inge Marie, Mikkelsen, S. U., Skov, V., Kjær, L., Hasselbalch, H. C. & Nielsen, C. H., 2019, In: European Journal of Haematology. 103, 4, p. 351-361 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Cancerimmunterapi til behandling af hæmatologisk cancer

    Holmström, M. O., Klausen, U., Jørgensen, N. G., Holmberg, S., Grauslund, J., Met, Ö., Svane, Inge Marie, Pedersen, Lars Møller, Knudsen, L. M., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2019, In: Ugeskrift for Laeger. 181, 10, 5 p., V06180421.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Chimeric antigen receptor-T-cellebehandling

    Muller, Klaus, Ifversen, M., Kielsen, K., Petersen, S. L., Met, Ö. & Svane, Inge Marie, 2019, In: Ugeskrift for Laeger. 181, 20A, 5 p., V05190309.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Collagen density regulates the activity of tumor-infiltrating T cells

    Kuczek, D. E., Larsen, A. M. H., Thorseth, M., Carretta, M., Kalvisa, A., Siersbæk, M. S., Simões, A. M. C., Roslind, A., Engelholm, Lars Henning, Noessner, E., dqp123, dqp123, Svane, Inge Marie, Straten, P. T., Grøntved, L. & Madsen, D. H., 2019, In: Journal for ImmunoTherapy of Cancer. 7, 1, 15 p., 68.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, Inge Marie, Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., 2019, In: Nature Medicine. 25, 6, p. 941-946 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs

    Draghi, A., Borch, T. H., Radic, H. D., Chamberlain, C. A., Gokuldass, A., Svane, Inge Marie & dqp123, dqp123, 2019, In: International Journal of Cancer. 145, 5, p. 1408-1413 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

    Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Geukes Foppen, M. H., Højberg, L., Schmidt, H., van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., Long, G. V. & 3 others, Atkinson, V., Blank, C. U. & Neyns, B., 2019, In: Annals of Oncology. 30, 7, p. 1154-1161 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 Next

ID: 4054758